TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Drug Reduction in Older Patients: The DROP Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Referred to SNF (per Physical Therapy and/or Social Work notes)~* Being discharged from the Nashville VA hospital from a medicine or orthopedics team~* Age \> or = 50~* Have polypharmacy, as defined by \> 5 medications based on pre-hospital and in-hospital medications~* Able to self-consent or has a surrogate~Exclusion Criteria:~* Resides in long-term care~* On hospice~* Not expected to discharge within 48 hours of referral

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control--usual care (Type: NO_INTERVENTION): Medication History: All participants / surrogates will receive a structured interview and chart review by the study Pharmacist or Nurse Practitioner at enrollment to determine:~Medications: Medications will include ANY medication with the potential for continuation at the time of hospital discharge to include pre-hospital medications, \[OTC medications\] and active in-hospital medications. Pre-hospital \[and OTC\] medications will be confirmed by Veteran/surrogate interview and pharmacy refills. If a Veteran is admitted from SNF (short-term stay), the investigators will request a copy of the Medication Administration Record (MAR) for the past 30 days. Current medications will be defined as those taken within 30 days prior to the index (enrollment) hospitalization event.
- Intervention--deprescribing protocol (Type: EXPERIMENTAL): In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent~* Diagnosis of papulopustular rosacea (IGA score of moderate or severe) with a minimum of 12 and maximum of 50 inflammatory lesions (papules and/or pustules) and persistent erythema with or without telangiectasia~* Free of any clinically significant disease which could interfere with the study~* Willingness to follow all study procedures~* Male or female patient at least 18 years of age~Exclusion Criteria:~* Subjects known to be non-responders to azelaic acid~* Presence of dermatoses that might interfere with the rosacea diagnosis or the evaluation of treatment results~* Ocular rosacea, phymatous rosacea~* Any condition or therapy that in the opinion of the investigator may pose a risk to the patient of interfere with any evaluation in the study~* Facial laser surgery in the 6 weeks prior to the study~* Topical or systemic use of prescription or non-prescription medications to treat rosacea~* Use of any agent other than the investigational drugs to treat rosacea during the study~* Expected use or change in dose in the 90 days prior to the study of beta-blockers, vasodilators, NSAIDs, hormonal treatment or drugs causing acneiform eruptions~* Known hypersensitivity to any ingredients of the investigational product formulation~* Alcohol or drug abuse~* Incapability of giving fully informed consent~* Subject is dependent person, i.e., a relative/family member of the investigator and/or is a member of the investigator's staff~* Participation in another clinical research study within the last 4 weeks before randomization in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azelaic acid foam, 15% (BAY39-6251) (Type: EXPERIMENTAL): Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
- Vehicle foam (Type: PLACEBO_COMPARATOR): Participants received vehicle foam topically twice daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Clinicians and Managers:~* Psychiatrists, Case Managers, Nurses, Supported Employment workers Nutritionists, Local Recovery Coordinators, and Quality Improvement experts working at one of the participating VA Medical Centers~Patients:~* At least 18 years old~* Diagnosis of Schizophrenia, Schizoaffective, or schizophreniform disorder~* At least 1 treatment visit with a clinician at the clinic during the 6 months prior to enrollment and then at least 1 treatment visit with a clinician at the clinic during the 5 months of enrollment.~Exclusion Criteria:~None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Collaborative Chronic Illness Care Model (Type: EXPERIMENTAL): Collaborative Chronic Illness Care Model: A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
- Usual Care (Type: NO_INTERVENTION): Usual Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Females only~* Consent for the collection of biopsy tissue in RNAlater solution~* Biopsy specimens that were obtained by core biopsy or incisional biopsy and placed in RNAlater solution~* Breast cancer that is:~  * unilateral~ * diagnosed histologically as invasive breast cancer without evidence of metastatic disease (except for stage IV with positive supraclavicular nodes only)~ * stage IIB, IIIA (T0-3N2), IIIB (T4N0-3 or T0-3N3), or IV (by involvement of positive supraclavicular nodes only). (Patients with clinical evidence of inflammatory breast cancer or superficial lesions must have a measurable mass in the breast or lymph nodes.)~ * measurable by physical exam, mammography, sonogram, CT scan, MRI, or x-ray~* Evidence of adequate organ function (liver, bone marrow, kidney)~* Ability to perform an adequate level of physical activity (Zubrod scale 0, 1, or 2)~* Life expectancy of at least 10 years~* Childbearing potential terminated by surgery, radiation, or menopause, or attenuated by use of an effective non-hormonal, barrier contraceptive method~* Disease-free from prior nonbreast malignancies for at least 5 years before entry~* Adequate cardiac function( measured by baseline LVEF on MUGA or echocardiogram greater than or equal to the institution's lower limit of normal)~Exclusion criteria:~* Male~* Hormonal birth control~* The use of hormonal agents or raloxifene~* Active infection~* Pregnancy or breastfeeding~* Bilateral malignancy or a mass in the opposite breast suspicious for malignancy, unless there is biopsy proof that the mass is not malignant~* Previous therapy for breast cancer~* Nonmalignant systemic disease that would keep the patient from being given the treatment or would prevent long-term follow-up~* Active cardiac disease that would preclude the use of epirubicin and/or Taxol~* Significant abnormal peripheral nerve disease (greater than or equal to Grade 2)~* Any prior anthracycline or taxane-containing chemotherapy~* Use of any investigational agent within one month before enrollment~* Excisional biopsy of the breast

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Caucasian Argentinean males and females volunteers aged 21 to 50 years with a body mass index from 19 to 27 kg/m2 were enrolled in this study.~* All volunteers provided written informed consent prior to study initiation.~Exclusion Criteria:~* History of cardiovascular, hepatic, renal, psychiatric, neurologic, hematologic, or metabolic disease~* Drug or alcohol abuse within 2 years before the start of the study~* Smoking~* HIV, hepatitis B, or hepatitis C infection~* Consumption of any prescribed or over-the-counter drug within 2 weeks before the study or~* Participation in a similar study within the past 6 months. Female subjects were not to be pregnant, planning to become pregnant, or breastfeeding at the time of the study, and were required to use an effective method of contraception (intrauterine device or hormonal method) throughout the study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Levodopa + benserazide (test formulation) (Type: EXPERIMENTAL): A randomized-sequence, open-label, 2-period crossover study assessing relative bioavailability of two drug products containing the association levodopa + benserazide.
- Levodopa + benserazide (reference formulation) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Written informed consent~* History of allergic rhino-conjunctivitis in spring and summer~* Age 18 years to 65 years~* Positive skin prick test to grass pollen~Exclusion criteria:~* Blood donation within previous 30 days~* Surgery within the previous 30 days~* Use of investigational drugs within previous 90 days~* Pregnancy or nursing~* Mastocytosis~* Significant cardiovascular disease~* Hypertension~* Active infectious disease~* Significant hepatic disease~* Significant renal disease~* Significant hematological disorder~* Significant pulmonary disease~* Moderate or severe asthma~* Autoimmune disease~* History of malignancy.~* Contraindicated medications were immunosuppressive agents, beta-blockers, ACE-inhibitors, and tricyclic antidepressants.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified adenocarcinoma arisen from gallbladder, extra or intrahepatic bile ducts or malignant cells consistent with the above and concomitant radiologic findings consistent with cholangiocarcinoma.~* Curative treatment presently discounted (surgery, stereotactic radiotherapy, etc.)~* KRAS analyzed and found wild-type (wt) or mutated~* PS 0-2~* Evaluable disease according to RECIST criteria, i.e., the disease does not need to be measurable~* Haematology:~  * ANC ≥ 1.5 x 10\^9/l~ * Thrombocytes ≥ 100x10\^9/l~* Biochemistry:~  * Bilirubinaemia ≤ 3 x upper normal value~ * ALAT ≤ 5 x upper normal value~* Creatinin ≤ upper normal value. If raised creatinin, the measured or calculated GFR must be at least 50% of the lower normal value.~* Fertile women must present a negative pregnancy test and use birth control during and 3 months after treatment. The following methods are considered safe birth control: Birth control pills, coil, gestagen deposit injection, subdermal implantation, hormonal vagina ring, and transdermal deposit band-aid)~* Oral and written informed consent~Exclusion Criteria:~* Chemotherapy within 4 weeks~* Radiotherapy within 4 weeks~* Immunotherapy within 4 weeks~* Other concomitant experimental treatment~* Known neuropathy ≥ grade 2~* Serious congruous medical disease~* Other previous malignant disease within 5 years, excl. non-melanoma skin cancer and carcinoma in situ cervicis uteri~* Previous serious and unexpected reactions to fluoropyrimidine treatment~* Hypersensitivity to one or more of the active substances, auxiliary substances or fluoruracil~* Patients with interstitial pneumonitis or pulmonary fibrosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- KRAS wildtype (Type: OTHER): None
- KRAS mutation (Type: OTHER): Inclusion has been completed in the KRAS mutation arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Prevention of Rabies Adopts 4-shot Immunization Method

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The age is 10-60 years old;~* Underarm temperature ≤ 37.0 ℃.~Exclusion Criteria:~* Have a history of rabies vaccine immunization or use of rabies virus passive immunization agents；~* Has been diagnosed with congenital or acquired immunodeficiency disease；~* Pregnancy (including positive urine pregnancy test) or lactation, planned pregnancy preparation within 2 months.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Experimental 4 doses (Type: EXPERIMENTAL): Inoculate experimental vaccine according to 2-1-1 immunization procedure
- Experimental 5 doses (Type: EXPERIMENTAL): Inoculate experimental vaccine according to 1-1-1-1-1 immunization procedure
- SPEEDA® 4 doses (Type: ACTIVE_COMPARATOR): Inoculate SPEEDA® according to 2-1-1 immunization procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 90 years of age inclusive~* Female patient is authorized to participate if at least one of the following criteria are met:~  1. Surgical sterilization~ 2. Age ≥50 years and postmenopausal as defined by amenorrhea for 12 months or more following cessation of all exogenous hormonal treatments~ 3. Age \<50 years and postmenopausal as defined by documented LH and FSH levels in the postmenopausal range PLUS amenorrhea for 12 months or more following cessation of all exogenous hormonal treatments~ 4. Patient has a negative serum pregnancy test (serum ß-human chorionic gonadotropin \[ß-hCG\]) within 1 day prior to study entry, and agrees to use highly effective contraception methods during treatment and for at least 7 days after last dose of IV study therapy~* Intraoperative/postoperative enrollment with confirmation (presence of pus within the abdominal cavity) of an intra-abdominal infection associated with peritonitis~* Confirmation of infection by surgical intervention within 24 hours of entry: evidence of systemic inflammatory response; physical findings consistent with intra-abdominal infection; supportive radiologic imaging findings of intra-abdominal infections~Exclusion Criteria:~* Patient is diagnosed with traumatic bowel perforation undergoing surgery within 12 hours; perforation of gastroduodenal ulcers undergoing surgery within 24 hours. Other intra-abdominal processes in which primary etiology is not likely to be infectious~* Patient has abdominal wall abscess or bowel obstruction without perforation or ischemic bowel without perforation~* Patient has suspected intra-abdominal infections due to fungus, parasites, virus or tuberculosis~* Patient is considered unlikely to survive the 6 to 8 week study period or has a rapidly progressive or terminal illness, including septic shock that is associated with a high risk of mortality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- CAZ-AVI + Metronidazole (Type: EXPERIMENTAL): IV treatment
- Meropenem (Type: ACTIVE_COMPARATOR): IV treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition - Text Revision (DSM-IV-TR) criteria for Adult Attention-Deficit/Hyperactivity Disorder (ADHD) as assessed by the Conners' Adult ADHD Diagnostic Interview for DSM-IV (CAADID).~* Have a Clinical Global Impression for ADHD Severity Score (CGI-ADHD-S) of 4 or greater Visit 2 and 3.~* Adult Men and Women age 18 years or older at time informed consent is obtained.~* Must be in a reciprocal relationship with a person of the opposite sex living in same defined household (cohabitating) with their spouse/significant other for a period of at least 3 months. This spouse/significant other cannot change during the study.~* Must have one or more children 6-17 years of age living the home as the primary residence.~Exclusion Criteria:~* Anyone meeting Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for any history of bipolar disorder or any history of a psychotic disorder.~* Anyone meeting diagnostic (DSM-IV) criteria for current major depression or current anxiety disorder.~* Taking psychotropic medications on a regular basis.~* Having any medical condition that would be exacerbated or not appropriate for inclusion in this trial.~* Previously taken an adequate trial of atomoxetine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): Atomoxetine 40 milligrams (mg) once daily (QD) for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is administered once daily (QD), orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Primary Inclusion Criteria:~* Diagnosis of RA for at least 1 year~* Failed at least 1 disease modifying anti-rheumatic drug (DMARD) due to toxicity or lack of efficacy. These drugs must include 1 or more of the following: methotrexate, parenteral gold, sulfasalazine, leflunomide, and tumor necrosis factor-alpha (TNFα) inhibitors (infliximab, etanercept or adalimumab)~* Active RA disease of at least moderate disease activity~* Be on a stable RA treatment regimen for at least the past 60 days (for DMARDS); if on non-steroidal anti-inflammatory drugs (NSAIDs) or steroids these must be at a stable dose for the last 30 days~Primary Exclusion Criteria:~* Received a non-FDA approved investigational agent within the last 28 days~* Currently receiving or received within the last 60 days the following: TNFα-inhibitors (infliximab, etanercept, adalimumab) or interleukin-1 receptor antagonist (anakinra)~* Currently receiving or received within the last 6 months the following: anti-CD20 antibody (rituximab) or cyclophosphamide~* Steroid injection into any joint within the last 30 days~* History of hypogammaglobulinemia or immunoglobulin A (IgA) deficiency~* History of chronic infection that has been active within last 6 months, or herpes zoster within last 90 days, or any infection requiring hospitalization or intravenous medication within last 60 days~* Human immunodeficiency virus (HIV), Hepatitis-B, Hepatitis-C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo plus SOC (Type: PLACEBO_COMPARATOR): None
- Belimumab 1 mg/kg plus SOC (Type: EXPERIMENTAL): None
- Belimumab 4 mg/kg plus SOC (Type: EXPERIMENTAL): None
- Belimumab 10 mg/kg plus SOC (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete